Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
CGNX Cognex Corp
SNTG Sentage Holdings Inc
XNXNX Nuveen New York Select Tax Free Income Portfolio
ITRI Itron Inc
NMZ Nuveen Municipal High Income Opportunity Fund
WTER Alkaline Water Company Inc
CASA Casa Systems Inc
PVBC Provident Bancorp Inc (Maryland)
AFRM Affirm Holdings Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Closing Price
$277.42
Day's Change
16.11 (6.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
278.25
Day's Low
256.64
Volume
(Average)
Volume:
1,303,903

10-day average volume:
1,249,254
1,303,903

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm

6:14 pm ET June 24, 2022 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Karuna Therapeutics, Inc. ("Karuna" or "the Company") (NASDAQ: KRTX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

info@schallfirm.com

www.schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128992

comtex tracking

COMTEX_409192592/2523/2022-06-24T18:14:09

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.